UB Paderborn / Katalog / Suche / in CDI

Actualités thérapeutiques dans les MICI

Côlon & rectum, 2017-08, Vol.11 (3), p.152-158

2017

Volltextzugriff (PDF)

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

Alimentary pharmacology & therapeutics, 2018-03, Vol.47 (5), p.588-595

2018

Volltextzugriff (PDF)

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Alimentary Pharmacology & Therapeutics (Suppl), 2017-08, Vol.46 (3), p.310-321

2017

Volltextzugriff (PDF)

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study

Digestive and liver disease, 2024-08, Vol.56 (8), p.1312-1318

2024

Volltextzugriff (PDF)

Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

Journal of Crohn's and colitis, 2022-11, Vol.16 (10), p.1523-1530

2022

Volltextzugriff (PDF)

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i1290-i1290

2024

Volltextzugriff (PDF)

DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i120-i120

2022

Volltextzugriff (PDF)

Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study

Journal of Crohn's and colitis, 2019-09, Vol.13 (9), p.1121-1130

2019

Volltextzugriff (PDF)

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study

Journal of Crohn's and colitis, 2019-01, Vol.13 (Supplement_1), p.S616-S616

2019

Volltextzugriff (PDF)

COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire

Revue du rhumatisme (Ed. française : 1993), 2021-12, Vol.88, p.A52-A53

2021

Volltextzugriff (PDF)

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

Alimentary pharmacology & therapeutics, 2018-02, Vol.47 (4), p.485-493

2018

Volltextzugriff (PDF)

First clinical case report of local microinjection of autologous fat and adipose-derived stromal vascular fraction for perianal fistula in Crohn's disease

Stem cell research & therapy, 2018-01, Vol.9 (1), p.4-4, Article 4

2018

Volltextzugriff (PDF)

P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study

Journal of Crohn's and colitis, 2024-01, Vol.18 (Supplement_1), p.i812-i812

2024

Volltextzugriff (PDF)

P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

Journal of Crohn's and colitis, 2023-02, Vol.17 (Supplement_1), p.i707-i707

2023

Volltextzugriff (PDF)

ePS2.04 Gastrointestinal surgery in adult patients with cystic fibrosis: observational French prospective study over 11 years

Journal of cystic fibrosis, 2020-06, Vol.19, p.S41-S41

2020

Volltextzugriff (PDF)

P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i223-i224

2022

Volltextzugriff (PDF)

Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

Journal of Crohn's and colitis, 2022, Vol.16 (1), p.I223-I224

2022

Volltextzugriff (PDF)

P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i362-i363

2022

Volltextzugriff (PDF)

DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i084-i085

2022

Volltextzugriff (PDF)

Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

Journal of Crohn's and colitis, 2022, Vol.16 (1), p.I362-I363

2022

Volltextzugriff (PDF)

P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

Journal of Crohn's and colitis, 2023-02, Vol.17 (Supplement_1), p.i572-i572

2023

Volltextzugriff (PDF)

P638 Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study

Journal of Crohn's and colitis, 2023-01, Vol.17 (Supplement_1), p.i770-i770

2023

Volltextzugriff (PDF)

P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i537-i537

2022

Volltextzugriff (PDF)

P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort

Journal of Crohn's and colitis, 2021-05, Vol.15 (Supplement_1), p.S305-S306

2021

Volltextzugriff (PDF)

P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

Journal of Crohn's and colitis, 2022-01, Vol.16 (Supplement_1), p.i265-i266

2022

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Actualités thérapeutiques dans les MICI

Long‐term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience

One‐year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study

Infliximab is an effective option in patients with ulcerative colitis previously exposed to full subcutaneous anti-TNF agent: Results from a real-world multicenter study

Comparative Risk of Incident Cancer in Patients with Inflammatory Bowel Disease with Prior Non-digestive Malignancy According to Immunomodulator: a Multicentre Cohort Study

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

DOP76 Real-world multicenter comparison of effectiveness between tofacitinib and vedolizumab in patients with Ulcerative Colitis after failure to at least one anti-TNF agent

Efficacy, Tolerability, and Safety of Low-Volume Bowel Preparations for Patients with Inflammatory Bowel Diseases: The French Multicentre CLEAN Study

Adalimumab for patients with Crohn’s disease complicated by intra-abdominal abscess: a multicentre, prospective, observational cohort study

COMBIO : efficacité et tolérance des associations de thérapies ciblées chez les patients atteints de maladies inflammatoires à médiation immunitaire

Impact of vedolizumab therapy on extra‐intestinal manifestations in patients with inflammatory bowel disease: a multicentre cohort study nested in the OBSERV‐IBD cohort

First clinical case report of local microinjection of autologous fat and adipose-derived stromal vascular fraction for perianal fistula in Crohn's disease

P386 Persistence of bowel urgency despite clinical remission after induction therapy is associated with unfavorable long-term outcomes in patients with ulcerative colitis: results from the multicenter UC-RGENCY study

P579 Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study

ePS2.04 Gastrointestinal surgery in adult patients with cystic fibrosis: observational French prospective study over 11 years

P142 Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

Inflammatory bowel diseases associated with primary immunodeficiency: a multicenter study

P350 Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

DOP36 Efficacy and safety of vedolizumab in patients with chronic active pouchitis refractory to anti-TNF therapy: Results of a retrospective multicenter study

Comparative risk of incident cancer in patients with Inflammatory Bowel Disease with prior non-digestive malignancy according to immunomodulator: a multicenter cohort study

P443 Risk of incident Cancer in Patients with Inflammatory Bowel Disease with Prior Breast Cancer: a Multicentre Cohort Study

P638 Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study

P604 Infection Risk in Elderly Patients with Inflammatory Bowel Disease under anti-TNF, ustekinumab or vedolizumab biologic therapies: A Prospective Multicenter observational One-Year follow-up comparative study

P272 Tofacitinib as salvage therapy for patients hospitalized with refractory severe active ulcerative colitis: a GETAID multicenter prospective/retrospective cohort

P207 COVID-19: a prevalence rate two times lower than that of the general population in French patients with Inflammatory Bowel Disease treated with intravenous biologic agents

Suchergebnisse filtern